

Neil M Ampel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8556481/publications.pdf>

Version: 2024-02-01

62
papers

3,636
citations

186209

28
h-index

133188

59
g-index

63
all docs

63
docs citations

63
times ranked

1504
citing authors

#	ARTICLE	IF	CITATIONS
1	Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2005, 41, 1217-1223.	2.9	602
2	2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2016, 63, e112-e146.	2.9	399
3	Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor γ antagonists. <i>Arthritis and Rheumatism</i> , 2004, 50, 1959-1966.	6.7	245
4	Coccidioidomycosis as a Common Cause of Community-acquired Pneumonia. <i>Emerging Infectious Diseases</i> , 2006, 12, 958-962.	2.0	234
5	Recent Advances in Our Understanding of the Environmental, Epidemiological, Immunological, and Clinical Dimensions of Coccidioidomycosis. <i>Clinical Microbiology Reviews</i> , 2013, 26, 505-525.	5.7	223
6	Coccidioidomycosis during Human Immunodeficiency Virus Infection. <i>Medicine (United States)</i> , 1990, 69, 384-391.	0.4	183
7	Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. <i>American Journal of Medicine</i> , 1993, 94, 235-240.	0.6	169
8	Coccidioidomycosis in Patients with HIV and A β 1 Infection in the Era of Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 50, 1-7.	2.9	102
9	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e364-e374.	4.6	99
10	Fungemia Due to <i>Coccidioides immitis</i> . <i>Medicine (United States)</i> , 1986, 65, 312-321.	0.4	80
11	Coccidioidomycosis in Persons Infected with HIV Type 1. <i>Clinical Infectious Diseases</i> , 2005, 41, 1174-1178.	2.9	73
12	Factors and Outcomes Associated with the Decision to Treat Primary Pulmonary Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2009, 48, 172-178.	2.9	73
13	A Major Cell Surface Antigen of <i>Coccidioides immitis</i> Which Elicits Both Humoral and Cellular Immune Responses. <i>Infection and Immunity</i> , 2000, 68, 584-593.	1.0	67
14	Coccidioidomycosis in Arizona: Increase in Incidence from 1990 to 1995. <i>Clinical Infectious Diseases</i> , 1998, 27, 1528-1530.	2.9	64
15	Bronchoscopic diagnosis of pulmonary coccidioidomycosis comparison of cytology, culture, and transbronchial biopsy. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 18, 83-87.	0.8	61
16	Coccidioidomycosis: A Review of Recent Advances. <i>Clinics in Chest Medicine</i> , 2009, 30, 241-251.	0.8	50
17	Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. <i>Arthritis Care and Research</i> , 2012, 64, 1903-1909.	1.5	47
18	THE TREATMENT OF COCCIDIOIDOMYCOSIS. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2015, 57, 51-56.	0.5	47

#	ARTICLE	IF	CITATIONS
19	New Perspectives on Coccidioidomycosis. Proceedings of the American Thoracic Society, 2010, 7, 181-185.	3.5	43
20	The Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis. Clinical Infectious Diseases, 2015, 61, 787-791.	2.9	43
21	The Complex Immunology of Human Coccidioidomycosis. Annals of the New York Academy of Sciences, 2007, 1111, 245-258.	1.8	39
22	Coccidioidomycosis in selected immunosuppressed hosts. Medical Mycology, 2019, 57, S56-S63.	0.3	38
23	Glucan-Chitin Particles Enhance Th17 Response and Improve Protective Efficacy of a Multivalent Antigen (rCpa1) against Pulmonary Coccidioides posadasii Infection. Infection and Immunity, 2018, 86, .	1.0	36
24	Reversal of Coccidioidal Energy In Vitro by Dendritic Cells from Patients with Disseminated Coccidioidomycosis. Journal of Immunology, 2002, 169, 2020-2025.	0.4	35
25	Cellular Immune Suppressor Activity Resides in Lymphocyte Cell Clusters Adjacent to Granulomata in Human Coccidioidomycosis. Infection and Immunity, 2005, 73, 3923-3928.	1.0	35
26	Extraction of serologic and delayed hypersensitivity antigens from spherules of Coccidioides immitis. Diagnostic Microbiology and Infectious Disease, 1988, 11, 65-80.	0.8	33
27	Spherules Derived from Coccidioides posadasii Promote Human Dendritic Cell Maturation and Activation. Infection and Immunity, 2006, 74, 2415-2422.	1.0	32
28	A Reformulated Spherule-Derived Coccidioidin (Spherusol) to Detect Delayed-Type Hypersensitivity in Coccidioidomycosis. Mycopathologia, 2012, 174, 353-358.	1.3	32
29	What's Behind the Increasing Rates of Coccidioidomycosis in Arizona and California?. Current Infectious Disease Reports, 2010, 12, 211-216.	1.3	28
30	Measurement of Cellular Immunity in Human Coccidioidomycosis. Mycopathologia, 2003, 156, 247-262.	1.3	24
31	Positron Emission Tomography in the Evaluation of Pulmonary Nodules Among Patients Living in a Coccidioidal Endemic Region. Lung, 2014, 192, 589-593.	1.4	24
32	An Archived Lot of Coccidioidin Induces Specific Coccidioidal Delayed-type Hypersensitivity and Correlates with in Vitro Assays of Coccidioidal Cellular Immune Response. Mycopathologia, 2006, 161, 67-72.	1.3	23
33	Enhanced Antibody Detection and Diagnosis of Coccidioidomycosis with the MiraVista IgG and IgM Detection Enzyme Immunoassay. Journal of Clinical Microbiology, 2017, 55, 893-901.	1.8	23
34	The Mannose Receptor Mediates the Cellular Immune Response in Human Coccidioidomycosis. Infection and Immunity, 2005, 73, 2554-2555.	1.0	22
35	Coccidioidomycosis in Persons Infected with HIV. Annals of the New York Academy of Sciences, 2007, 1111, 336-342.	1.8	21
36	Central Nervous System Infections Due to Coccidioidomycosis. Journal of Fungi (Basel, Switzerland), 2019, 5, 54.	1.5	21

#	ARTICLE	IF	CITATIONS
37	Treatment for Early, Uncomplicated Coccidioidomycosis: What Is Success?. <i>Clinical Infectious Diseases</i> , 2020, 70, 2008-2012.	2.9	20
38	Polyfunctional T Lymphocytes Are in the Peripheral Blood of Donors Naturally Immune to Coccidioidomycosis and Are Not Induced by Dendritic Cells. <i>Infection and Immunity</i> , 2010, 78, 309-315.	1.0	19
39	In Vitro Whole-Blood Analysis of Cellular Immunity in Patients with Active Coccidioidomycosis by Using the Antigen Preparation T27K. <i>Vaccine Journal</i> , 2002, 9, 1039-1043.	3.2	18
40	In vitro modulation of cytokine production by lymphocytes in human coccidioidomycosis. <i>Cellular Immunology</i> , 2003, 221, 115-121.	1.4	18
41	Immunological Characterization of Bronchoalveolar Lavage Fluid in Patients With Acute Pulmonary Coccidioidomycosis. <i>Journal of Infectious Diseases</i> , 2013, 208, 857-863.	1.9	17
42	Persistent Coccidioidal Seropositivity Without Clinical Evidence of Active Coccidioidomycosis in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1995, 20, 1281-1285.	2.9	16
43	Coccidioidomycosis: Changing Concepts and Knowledge Gaps. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 354.	1.5	16
44	Fatigue in coccidioidomycosis. Quantification and correlation with clinical, immunological, and nutritional factors. <i>Medical Mycology</i> , 2006, 44, 585-590.	0.3	15
45	Preliminary Evaluation of Whole-Blood Gamma Interferon Release for Clinical Assessment of Cellular Immunity in Patients with Active Coccidioidomycosis. <i>Vaccine Journal</i> , 2005, 12, 700-704.	3.2	11
46	Mannose-Binding Lectin Serum Levels are Low in Persons with Clinically Active Coccidioidomycosis. <i>Mycopathologia</i> , 2009, 167, 173-180.	1.3	11
47	Coccidioidomycosis among persons undergoing lung transplantation in the coccidioidal endemic region. <i>Transplant Infectious Disease</i> , 2017, 19, e12713.	0.7	11
48	Ex Vivo Cytokine Release, Determined by a Multiplex Cytokine Assay, in Response to Coccidioidal Antigen Stimulation of Whole Blood among Subjects with Recently Diagnosed Primary Pulmonary Coccidioidomycosis. <i>MSphere</i> , 2018, 3, .	1.3	11
49	Discrepancy between growth of <i>Coccidioides immitis</i> in bacterial blood culture media and a radiometric growth index. <i>Diagnostic Microbiology and Infectious Disease</i> , 1988, 9, 7-10.	0.8	10
50	Combating opportunistic infections: coccidioidomycosis. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 255-261.	0.9	10
51	Cytokine Profiles from Antigen-Stimulated Whole-Blood Samples among Patients with Pulmonary or Nonmeningeal Disseminated Coccidioidomycosis. <i>Vaccine Journal</i> , 2015, 22, 917-922.	3.2	10
52	Measuring Cellular Immunity in Coccidioidomycosis: The Time is Now. <i>Mycopathologia</i> , 2010, 169, 425-426.	1.3	8
53	Controversies in the Management of Central Nervous System Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2022, 75, 555-559.	2.9	8
54	Coccidioidomycosis and COVID-19 Infection. An Analysis from a Single Medical Center Within the Coccidioidal Endemic Area. <i>Mycopathologia</i> , 2022, 187, 199-204.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Pathogenesis of Coccidioidomycosis. <i>Current Fungal Infection Reports</i> , 2015, 9, 253-258.	0.9	6
56	An Analysis of Skin Test Responses to Spherulin-Based Coccidioidin (Spherusol [®]) Among a Group of Subjects with Various Forms of Active Coccidioidomycosis. <i>Mycopathologia</i> , 2019, 184, 533-538.	1.3	6
57	Cavitary Coccidioidomycosis: Impact of azole antifungal therapy. <i>Medical Mycology</i> , 2021, 59, 834-841.	0.3	4
58	Management of asymptomatic coccidioidomycosis in patients with rheumatic diseases. <i>Rheumatology International</i> , 2019, 39, 1257-1262.	1.5	3
59	Dual-Time-Point FDG PET/CT to Distinguish Coccidioidal Pulmonary Nodules from Those Due to Malignancy. <i>Lung</i> , 2015, 193, 863-864.	1.4	2
60	Fungal Pathogenesis: Principles and Clinical Applications:Fungal Pathogenesis: Principles and Clinical Applications. <i>Clinical Infectious Diseases</i> , 2002, 34, 1291-1291.	2.9	1
61	Development of an Improved Antibody Detection EIA for Use in Diagnosis of Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
62	Whole-Blood Cytokine Analysis in Patients with Recently Diagnosed Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0